Published in Oncologist on January 01, 1998
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch (2010) 2.72
Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer (2005) 2.02
HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma. Dig Dis Sci (2008) 1.45
Depletion of kinesin 5B affects lysosomal distribution and stability and induces peri-nuclear accumulation of autophagosomes in cancer cells. PLoS One (2009) 1.30
IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production. J Immunol (2011) 1.25
HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther (2013) 1.23
Targeted therapy for HER2 positive breast cancer. J Hematol Oncol (2013) 1.19
Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother (2010) 1.12
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer (2006) 1.12
Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer. Ann Oncol (2009) 1.00
Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond. Epigenetics (2013) 0.99
Mammographic density and hormone receptor expression in breast cancer: the Multiethnic Cohort Study. Cancer Epidemiol (2011) 0.97
relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor. Theor Biol Med Model (2007) 0.96
HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study. J Cell Mol Med (2008) 0.95
ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation. Clin Cancer Res (2009) 0.93
β-catenin and Her2/neu expression in rectal cancer: association with histomorphological response to neoadjuvant therapy and prognosis. Int J Colorectal Dis (2011) 0.91
A comparison of image contrast with (64)Cu-labeled long circulating liposomes and (18)F-FDG in a murine model of mammary carcinoma. Am J Nucl Med Mol Imaging (2013) 0.90
Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters. Cancer Chemother Pharmacol (2013) 0.90
Molecular and genetic prognostic factors of prostate cancer. World J Urol (2003) 0.89
Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification. Breast Cancer Res (2007) 0.89
EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas. Virchows Arch (2012) 0.88
Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer. BMC Cancer (2014) 0.87
Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer. Pharmgenomics Pers Med (2013) 0.86
Molecular modeling of nearly full-length ErbB2 receptor. Biophys J (2004) 0.85
Ku proteins interact with activator protein-2 transcription factors and contribute to ERBB2 overexpression in breast cancer cell lines. Breast Cancer Res (2009) 0.84
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. Breast Cancer Res Treat (2013) 0.83
Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast. Cancer Immun (2010) 0.83
Quantification of kinase activity in cell lysates via photopatterned macroporous poly(ethylene glycol) hydrogel arrays in microfluidic channels. Biomed Microdevices (2012) 0.83
Molecular imaging agents: impact on diagnosis and therapeutics in oncology. Expert Rev Mol Med (2010) 0.82
A gene expression profile indicative of early stage HER2 targeted therapy response. Mol Cancer (2013) 0.82
Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer. J Cancer Res Clin Oncol (2015) 0.82
Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. Br J Cancer (2002) 0.81
Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics. Diagn Pathol (2015) 0.80
Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer. Oncologist (2012) 0.79
Lead sulfide near-infrared quantum dot bioconjugates for targeted molecular imaging. Int J Nanomedicine (2007) 0.78
HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy. PLoS One (2016) 0.77
A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis. Mol Ther (2015) 0.76
Role of traditional and new biomarkers in breast carcinogenesis. Ecancermedicalscience (2009) 0.75
Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output. Proc Natl Acad Sci U S A (2014) 0.75
Biological markers and response to neoadjuvant taxane-based chemotherapy in patients with locally advanced breast cancer. ISRN Oncol (2012) 0.75
Potential Therapeutic Targets in Uterine Sarcomas. Sarcoma (2015) 0.75
Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions. Int J Mol Sci (2016) 0.75
Therapeutic implication of HER2 in advanced biliary tract cancer. Oncotarget (2016) 0.75
Role of hormonal risk factors in HER2-positive breast carcinomas. Br J Cancer (2003) 0.75
HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. Oncotarget (2016) 0.75
Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab. Cancer Manag Res (2016) 0.75
Expression of Concern. Oncologist (2016) 0.75
Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3. J Ovarian Res (2014) 0.75
Molecular characterization of breast cancer cell lines by clinical immunohistochemical markers. Oncol Lett (2017) 0.75
BiHC, a T-Cell-Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells. Transl Oncol (2017) 0.75
A method for testing association patterns of social animals. Anim Behav (1998) 3.27
Obesity : impact on cardiovascular disease Circulation (1998) 1.51
Patient satisfaction needs as related to knee stability and objective findings after ACL reconstruction using the LARS artificial ligament. Knee (2000) 1.29
Effects of relatedness on queen competition within honey bee colonies Anim Behav (1998) 0.91
Low-field transport coefficients in GaAs/Ga1-xAlxAs heterostructures. Phys Rev B Condens Matter (1989) 0.83
Magnetothermoelectric properties of the degenerate semiconductor HgSe:Fe. Phys Rev B Condens Matter (1996) 0.81
Thermoelectric properties of GaAs-Ga1-xAlxAs heterojunctions at high magnetic fields. Phys Rev B Condens Matter (1986) 0.80
Indications for Cardiac Pacemaker Implantation in Myotonic Dystrophy. MedGenMed (1999) 0.80
Thermoelectric properties of a very-low-mobility two-dimensional electron gas. Phys Rev B Condens Matter (1994) 0.80
SHRIMP uranium-lead dating of diagenetic xenotime in siliciclastic sedimentary rocks Science (1999) 0.79
The influence of queen age and quality during queen replacement in honeybee colonies. Anim Behav (2000) 0.78